Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...
A quadruplet regimen is now the preferred first-line treatment for multiple myeloma in both transplant-eligible and ...
A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...
Zacks.com on MSN21h
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaThe FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.
GlobalData on MSN4d
Health Canada issues NOC to J&J’s CARVYKTI for multiple myelomaThe study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.
Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...
Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...
News Medical on MSN12d
Scientists create an scRNA-seq atlas of the multiple myeloma immune microenvironment across disease stagesMultiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...
MedPage Today on MSN8d
The Evolving Role of MRD in Managing Multiple Myeloma"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback